PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

  • Retrospective study evaluated the efficacy and safety of HIVEC® with mitomycin C in patients treated at the Erasmus Medical Center and Amphia hospital between 2015 and 2022
  • Real-world data support HIVEC® as a bladder-preserving alternative to radical cystectomy
  • Evidence presented at the European Multidisciplinary Congress on Urological Cancers (EMUC), held 5-8 November 2026, Brussels

Combat Medical, a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) after hyperthermic intravesical chemotherapy (HIVEC®) with mitomycin C. The findings of the retrospective study of 150 patients further support HIVEC as a bladder-preserving treatment option for patients facing radical cystectomy.

The data was presented at the 18th European Multidisciplinary Congress on Urological Cancers (EMUC) by Dr Yoran Tomassen from the Erasmus Medical Center (Erasmus MC)1.

Radical cystectomy is the recommended treatment for patients with BCG-unresponsive NMIBC. However, many patients are medically unfit for surgery or decline the procedure due to its complexity, high risk of complications and life-altering impact post-surgery. The Combat bladder recirculation system (BRS), developed using the Company’s patented hyperthermic platform technology, delivers HIVEC at precisely controlled temperatures to enhance the cytotoxic effect of treatment while offering a bladder-preserving alternative.

The retrospective study, conducted by the Erasmus MC, evaluated patients with BCG-unresponsive NMIBC, who received HIVEC with mitomycin C using the Combat BRS at the Erasmus MC and Amphia hospital in The Netherlands between 2015 and 2022. Key findings:

  • 150 BCG Unresponsive patients
  • 68% HG-RFS at 12 months (all patients)
  • 83% HG-RFS at 12 months (papillary only patients)
  • 61% HG-RFS at 12 months (CIS only patients)
  • 56% complete response at 6 months in patients with CIS; response maintained at 12 months in 68% of responders
  • 92% progression-free survival at 12 months
  • 21-month median follow up
  • Well tolerated, 12% Adverse Events report, with 99% grade 1 & 2

Edward Bruce-White, Chief Executive Officer of Combat Medical, commented: “This study demonstrates HIVEC’s efficacy and tolerability in patients with BCG-unresponsive NMIBC and provides real-world evidence to support the potential of HIVEC as a highly effective bladder-preserving treatment option for patients who are unwilling or unfit to undergo radical cystectomy. Confirmation in our prospective HIVEC HEAT trial will establish HIVEC as a leading treatment option in this challenging patient population.”

Professor Joost Boormans, MD, PhD, Head of the Department of Urology at Erasmus Medical Center, added: “Treatment pathways for patients with BCG-unresponsive NMIBC are clinically challenging, particularly when radical cystectomy is not an appropriate option. Through this study, we have demonstrated the ability of HIVEC to achieve meaningful cancer control while maintaining a favourable safety profile, supporting its potential as an effective bladder-preserving treatment for routine clinical practice.”

  1. Tomassen Y.L. et al. Hyperthermic intravesical mitomycin C in BCG-unresponsive non-muscle-invasive bladder cancer

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC